Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Authors

Mathurin Flamant (ORCID: https://orcid.org/0000-0002-8076-7046)
Fabienne Coury (ORCID: https://orcid.org/0000-0002-9175-8620)
Janet Addison
Carine Salliot (ORCID: https://orcid.org/0000-0003-1066-4161)
Ben Braithwaite (ORCID: https://orcid.org/0000-0002-7378-1034)
Bruno Fautrel (ORCID: https://orcid.org/0000-0001-8845-4274)
Franck Carbonnel (ORCID: https://orcid.org/0000-0002-4779-5168)
Yves Maugars (ORCID: https://orcid.org/0000-0002-5131-8524)
Mathurin Fuméry (ORCID: https://orcid.org/0000-0002-2337-2902)
Yoram Bouhnik (ORCID: https://orcid.org/0000-0002-5787-4943)
Salima Hateb
Christophe Bernardeau

Institutions

Université Claude Bernard Lyon 1 (FR)
Inserm (FR)
Sanofi (France) (FR)
Centre Hospitalier Universitaire de Nantes (FR)
Sorbonne Université (FR)
Biogen (United Kingdom) (GB)
Centre Hospitalier Universitaire Amiens-Picardie (FR)
Assistance Publique – Hôpitaux de Paris (FR)
Hospices Civils de Lyon (FR)
Centre hospitalier universitaire d'Orléans (FR)
Clinique Hartmann (FR)
Clinique Ambroise Paré (FR)
Association François Aupetit (FR)
Clinique Jules Verne (FR)
Bicêtre Hospital (FR)
Nantes Université (FR)

Publication Details

Journal: Drugs - Real World Outcomes
Published: 2024-10-10
DOI: https://doi.org/10.1007/s40801-024-00459-6
Citations: 1
Primary Topic: Biosimilars and Bioanalytical Methods
Type: article
Field-Weighted Citation Impact: 0.24

Funders

Biogen

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Mathurin Flamant, Fabienne Coury, Janet Addison, Carine Salliot et al.

Oct 10, 2024

1 citations

Drugs - Real World Outcomes

Biosimilars and Bioanalytical Methods

0.24

article

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Mathurin Flamant, Fabienne Coury, Janet Addison, Carine Salliot, Ben Braithwaite, Bruno Fautrel, Franck Carbonnel, Yves Maugars, Mathurin Fuméry, Yoram Bouhnik, Salima Hateb, Christophe Bernardeau

October 10, 2024article en

1 citations

Abstract

No abstract available for this paper.

Drugs - Real World OutcomesVol. 11(4)

Université Claude Bernard Lyon 1 (FR), Inserm (FR), Sanofi (France) (FR), Centre Hospitalier Universitaire de Nantes (FR), Sorbonne Université (FR), Biogen (United Kingdom) (GB), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Centre hospitalier universitaire d'Orléans (FR), Clinique Hartmann (FR), Clinique Ambroise Paré (FR), Association François Aupetit (FR), Clinique Jules Verne (FR), Bicêtre Hospital (FR), Nantes Université (FR)

Biogen

Good health and well-being, Zero hunger

Openalex Percentile: Top 42%

Biosimilars and Bioanalytical Methods

0.24

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study — Mathurin Flamant, Fabienne Coury, et al. · Drugs - Real World Outcomes (2024) | TGRS Research Map | TGRS